Status:
WITHDRAWN
The Safety and Efficacy of Spherical Microwave Ablation for the Treatment of Malignant Liver Tumors
Lead Sponsor:
National Taiwan University Hospital
Conditions:
Hepatocellular Carcinoma (HCC)
Eligibility:
All Genders
20+ years
Phase:
NA
Brief Summary
Liver cancer including primary hepatocellular carcinoma (HCC) and metastatic liver cancers is one the most common malignancies in the world. Over 10000 new cases per year are diagnosed in Taiwan. Seve...
Detailed Description
Liver cancer including primary hepatocellular carcinoma (HCC) and metastatic liver cancers is one the most common malignancies in the world. Over 10000 new cases per year are diagnosed in Taiwan. Desp...
Eligibility Criteria
Inclusion
- Patients must meet all of the following inclusion criteria to be eligible for this study:
- The diagnosis of hepatocellular carcinoma (HCC) or metastatic liver cancers with pathologic proven, and the diagnosis of HCC will be made by pathology / cytology or according to the AASLD(2010) diagnostic criteria. In brief, Nodules larger than 1 cm found on ultrasound screening of a cirrhotic liver should be investigated further with either tri-phase multidetector CT scan or dynamic contrast enhanced MRI. If the appearances are typical of HCC (i.e., hypervascular in the arterial phase with washout in the portal venous or delayed phase), the lesion should be treated as HCC. If the findings are not characteristic or the vascular profile is not typical, a second contrast enhanced study with the other imaging modality should be performed, or the lesion should be biopsied. Biopsies of small lesions should be evaluated by expert pathologists. Tissue that is not clearly HCC should be stained with all the available markers including CD34, CK7, glypican 3, HSP-70, and glutamine synthetase to improve diagnostic accuracy.
- Unsuitable for surgical resection but local ablation is indicated, however, the distance between tumour and inferior vena cava is smaller than 1 cm.
- Have at least one, but less than or equal to 3 tumors,
- Each tumor must be ≤ 5 cm in diameter,
- Child-Pugh class A-B,
- Eastern Cooperative Oncology Group (ECOG) score of 0-1,
- American Society of Anaesthesiologists (ASA) score ≤ 3,
- Adequate bone marrow and liver function (1). Platelet count ≥ 100 K/Μl(2). Total bilirubin ≦ 3 mg/dL(3). ALT and AST \< 5 x upper limit of normal (4). PT-INR ≦ 2.0.
- The disease status is not suitable to receive transarterial chemoembolization or other standard treatment.
- Prior Informed Consent Form
- Life expectancy of at least 3 months.
- Exclusion criteria
- Patients presenting with any of the following will not be enrolled into this study:
- Women who are pregnant or women of child-bearing potential who are not using an acceptable method of contraception,
- Received treatment with an investigational agent/ procedure within 30 days prior to microwave ablation
- Patients who cannot tolerate RFA procedure, including the patients have tumors closed to gall bladder, pancreas, liver hilum and main bile ducts
- Acute infection or inflammation, acute and severe dysfunction of heart, liver and kidney, and the patients with metallic implantation including pacemaker.
- Known history of HIV infection
- Concurrent extrahepatic cancer
Exclusion
Key Trial Info
Start Date :
September 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 22 2020
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04044326
Start Date
September 1 2019
End Date
January 22 2020
Last Update
September 14 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Taiwan University Hospital
Taipei, Test2, Taiwan, 100